Clearside Biomedical CMO/CVO Thomas Ciulla resigns effective Feb 17; will serve as advisor

Clearside Biomedical, Inc.

Thomas Ciulla resigns as Chief Medical Officer and Chief Development Officer of Clearside Biomedical.
Resignation effective February 17, 2023; he will continue as Chairman of Scientific Advisory Board.
Ciulla will also serve as Chief Medical Advisor – Retina under a proposed consulting agreement.
No successor named; Ciulla’s advisory role aims to maintain continuity in clinical development.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Thomas Ciulla

Chief Medical Officer and Chief Development Officer

CLSDQ · Clearside Biomedical, Inc.

Effective: 2023-02-17
Filed: February 6, 2023, 6:59 PM ET

On February 2, 2023, Thomas Ciulla provided Clearside Biomedical, Inc. (the “ Company ”) notice of his resignation from his position as Chief Medical Officer and Chief Development Officer of the Company, with such resignation to be effective on February 17. 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Thomas Ciulla resigned as Chief Medical Officer and Chief Development Officer at Clearside Biomedical, Inc..

Action: resigned
Role: Chief Medical Officer and Chief Development Officer

Exact text from the filing

On February 2, 2023, Thomas Ciulla provided Clearside Biomedical, Inc. (the “ Company ”) notice of his resignation from his position as Chief Medical Officer and Chief Development Officer of the Company, with such resignation to be effective on February 17. 2023

View on SEC.gov

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-001831

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.